BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Advanced Drug Delivery Reviews 2017;118:65-77. [DOI: 10.1016/j.addr.2017.06.013] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Fernández-Sáez N, Rubio-Ruiz B, Campos JM, Unciti-Broceta A, Carrión MD, Camacho ME. Purine derivatives with heterocyclic moieties and related analogs as new antitumor agents. Future Med Chem 2019;11:83-95. [PMID: 30644318 DOI: 10.4155/fmc-2018-0291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Schnaars C, Kildahl-andersen G, Prandina A, Popal R, Radix S, Le Borgne M, Gjøen T, Andresen AMS, Heikal A, Økstad OA, Fröhlich C, Samuelsen Ø, Lauksund S, Jordheim LP, Rongved P, Åstrand OAH. Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-β-lactamase Inhibitors. ACS Infect Dis 2018;4:1407-22. [DOI: 10.1021/acsinfecdis.8b00137] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
3 Chen KJ, Plaunt AJ, Leifer FG, Kang JY, Cipolla D. Recent advances in prodrug-based nanoparticle therapeutics. Eur J Pharm Biopharm 2021;165:219-43. [PMID: 33979661 DOI: 10.1016/j.ejpb.2021.04.025] [Reference Citation Analysis]
4 Zhao J, Zhang B, Mao Q, Ping K, Zhang P, Lin F, Liu D, Feng Y, Sun M, Zhang Y, Li QH, Zhang T, Mou Y, Wang S. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis. J Med Chem 2022. [PMID: 35275619 DOI: 10.1021/acs.jmedchem.1c02166] [Reference Citation Analysis]
5 Cao Y, Liang Q, Lan Y, Liu Y. The therapeutic efficacy and safety improvements of crizotinib prodrug micelles on breast cancer treatment. Pharm Dev Technol 2022;:1-14. [PMID: 35579888 DOI: 10.1080/10837450.2022.2078984] [Reference Citation Analysis]
6 Subbaiah MAM, Ramar T, Subramani L, Desai SD, Sinha S, Mandlekar S, Jenkins SM, Krystal MR, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Kadow JF, Meanwell NA. (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration. Eur J Med Chem 2020;207:112749. [PMID: 33065417 DOI: 10.1016/j.ejmech.2020.112749] [Reference Citation Analysis]
7 Städler B, Zelikin AN. Enzyme prodrug therapies and therapeutic enzymes. Advanced Drug Delivery Reviews 2017;118:1. [DOI: 10.1016/j.addr.2017.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
8 Cheng L, Zhang F, Wang S, Pan X, Han S, Liu S, Ma J, Wang H, Shen H, Liu H, Yuan Q. Activation of Prodrugs by NIR-Triggered Release of Exogenous Enzymes for Locoregional Chemo-photothermal Therapy. Angew Chem Int Ed Engl 2019;58:7728-32. [PMID: 30964594 DOI: 10.1002/anie.201902476] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
9 Souza C, Pellosi DS, Tedesco AC. Prodrugs for targeted cancer therapy. Expert Rev Anticancer Ther 2019;19:483-502. [PMID: 31055990 DOI: 10.1080/14737140.2019.1615890] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Walther R, Jarlstad Olesen MT, Zelikin AN. Extended scaffold glucuronides: en route to the universal synthesis of O -aryl glucuronide prodrugs. Org Biomol Chem 2019;17:6970-4. [DOI: 10.1039/c9ob01384a] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yang T, Zelikin AN, Chandrawati R. Enzyme Mimics for the Catalytic Generation of Nitric Oxide from Endogenous Prodrugs. Small 2020;16:1907635. [DOI: 10.1002/smll.201907635] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Yang T, Zelikin AN, Chandrawati R. Progress and Promise of Nitric Oxide-Releasing Platforms. Adv Sci (Weinh) 2018;5:1701043. [PMID: 29938181 DOI: 10.1002/advs.201701043] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 16.5] [Reference Citation Analysis]
13 Yin J, Wang X, Sun X, Dai H, Song X, Li B, Zhang Y, Chen P, Dong X. Thrombin Based Photothermal-Responsive Nanoplatform for Tumor-Specific Embolization Therapy. Small 2021;:e2105033. [PMID: 34729905 DOI: 10.1002/smll.202105033] [Reference Citation Analysis]
14 Wang F, Yang J, Li Y, Zhuang Q, Gu J. Efficient enzyme-activated therapy based on the different locations of protein and prodrug in nanoMOFs. J Mater Chem B 2020;8:6139-47. [PMID: 32568339 DOI: 10.1039/d0tb01004a] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sun B, Luo C, Zhang X, Guo M, Sun M, Yu H, Chen Q, Yang W, Wang M, Zuo S, Chen P, Kan Q, Zhang H, Wang Y, He Z, Sun J. Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy. Nat Commun 2019;10:3211. [PMID: 31324811 DOI: 10.1038/s41467-019-11193-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 20.7] [Reference Citation Analysis]
16 Plunk MA, Quintana JM, Darden CM, Lawrence MC, Naziruddin B, Kane RR. Design and Catalyzed Activation of Mycophenolic Acid Prodrugs. ACS Med Chem Lett 2021;12:812-6. [PMID: 34055230 DOI: 10.1021/acsmedchemlett.1c00079] [Reference Citation Analysis]
17 Zhang L, Ma X, Zhou W, Wu Q, Yan J, Xu X, Ghimire B, Rosenholm JM, Feng J, Wang D, Zhang H. Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment. Materials Today Advances 2022;13:100199. [DOI: 10.1016/j.mtadv.2021.100199] [Reference Citation Analysis]
18 Japir AAMM, Ke W, Li J, Mukerabigwi JF, Ibrahim A, Wang Y, Li X, Zhou Q, Mohammed F, Ge Z. Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy. J Control Release 2021;339:418-29. [PMID: 34662586 DOI: 10.1016/j.jconrel.2021.10.015] [Reference Citation Analysis]
19 Wang Z, Yang L. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges. J Med Virol 2021. [PMID: 34897729 DOI: 10.1002/jmv.27517] [Reference Citation Analysis]
20 Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, Wang M, Kan Q, Zhang H, Wang Y, He Z, Sun J. Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy. Nano Lett 2018;18:3643-50. [PMID: 29726685 DOI: 10.1021/acs.nanolett.8b00737] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 33.3] [Reference Citation Analysis]
21 Hou DY, Wang MD, Zhang NY, Xu S, Wang ZJ, Hu XJ, Lv GT, Wang JQ, Lv MY, Yi L, Wang L, Cheng DB, Sun T, Wang H, Xu W. A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer. Nano Lett 2022. [PMID: 35548949 DOI: 10.1021/acs.nanolett.2c00540] [Reference Citation Analysis]
22 Yan J, Liu C, Wu Q, Zhou J, Xu X, Zhang L, Wang D, Yang F, Zhang H. Mineralization of pH-Sensitive Doxorubicin Prodrug in ZIF-8 to Enable Targeted Delivery to Solid Tumors. Anal Chem 2020;92:11453-61. [PMID: 32664723 DOI: 10.1021/acs.analchem.0c02599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
23 Wang X, Wang X, Jin S, Muhammad N, Guo Z. Stimuli-Responsive Therapeutic Metallodrugs. Chem Rev 2019;119:1138-92. [PMID: 30299085 DOI: 10.1021/acs.chemrev.8b00209] [Cited by in Crossref: 186] [Cited by in F6Publishing: 162] [Article Influence: 46.5] [Reference Citation Analysis]
24 Hou J, Pan Y, Zhu D, Fan Y, Feng G, Wei Y, Wang H, Qin K, Zhao T, Yang Q, Zhu Y, Che Y, Liu Y, Cheng J, Kong D, Wang PG, Shen J, Zhao Q. Targeted delivery of nitric oxide via a 'bump-and-hole'-based enzyme-prodrug pair. Nat Chem Biol 2019;15:151-60. [PMID: 30598545 DOI: 10.1038/s41589-018-0190-5] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
25 Hu Y, Epling D, Shi J, Song F, Tsume Y, Zhu HJ, Amidon GL, Smith DE. Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochem Pharmacol 2018;156:147-56. [PMID: 30121252 DOI: 10.1016/j.bcp.2018.08.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Wang Y, Douglas T. Protein nanocage architectures for the delivery of therapeutic proteins. Current Opinion in Colloid & Interface Science 2021;51:101395. [DOI: 10.1016/j.cocis.2020.101395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Yang Y, Zuo S, Zhang J, Liu T, Li X, Zhang H, Cheng M, Wang S, He Z, Sun B, Sun J. Prodrug nanoassemblies bridged by Mono-/Di-/Tri-sulfide bonds: Exploration is for going further. Nano Today 2022;44:101480. [DOI: 10.1016/j.nantod.2022.101480] [Reference Citation Analysis]
28 Ximenis M, Sampedro A, Martínez-crespo L, Ramis G, Orvay F, Costa A, Rotger C. Introducing a squaramide-based self-immolative spacer for controlled drug release. Chem Commun 2021;57:2736-9. [DOI: 10.1039/d0cc07683j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ghawanmeh AA, Chong KF, Sarkar SM, Bakar MA, Othaman R, Khalid RM. Colchicine prodrugs and codrugs: Chemistry and bioactivities. Eur J Med Chem 2018;144:229-42. [PMID: 29274490 DOI: 10.1016/j.ejmech.2017.12.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
30 Shi J, Wu P, Li H, Wei X, Jiang Z. Synthesis and anticancer activity of Boc-Gly-Pro dipeptide-annonaceous acetogenin prodrugs targeting fibroblast activation protein or other hydrolytic enzymes. Med Chem Res. [DOI: 10.1007/s00044-022-02857-3] [Reference Citation Analysis]
31 Zhao J, Wang Z, Zhong M, Xu Q, Li X, Chang B, Fang J. Integration of a Diselenide Unit Generates Fluorogenic Camptothecin Prodrugs with Improved Cytotoxicity to Cancer Cells. J Med Chem 2021;64:17979-91. [PMID: 34852457 DOI: 10.1021/acs.jmedchem.1c01362] [Reference Citation Analysis]
32 Okoh OA, Klahn P. Trimethyl Lock: A Multifunctional Molecular Tool for Drug Delivery, Cellular Imaging, and Stimuli-Responsive Materials. ChemBioChem 2018;19:1668-94. [DOI: 10.1002/cbic.201800269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
33 Walther R, Akker W, Fruergaard AS, Zelikin AN. Nanozymes and Glucuronides: Glucuronidase, Esterase, and/or Transferase Activity. Small 2020;16:2004280. [DOI: 10.1002/smll.202004280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Huang L, Zhao S, Fang F, Xu T, Lan M, Zhang J. Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy. Biomaterials 2021;268:120557. [PMID: 33260095 DOI: 10.1016/j.biomaterials.2020.120557] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
35 Shao C, Zhu Y, Lai Z, Tan P, Shan A. Antimicrobial peptides with protease stability: progress and perspective. Future Medicinal Chemistry 2019;11:2047-50. [DOI: 10.4155/fmc-2019-0167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
36 Bouzriba C, Chavez Alvarez AC, Gagné-Boulet M, Ouellette V, Lacroix J, Côté MF, C-Gaudreault R, Fortin S. Branched alkyl of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as unique cytochrome P450 1A1-activated antimitotic prodrugs: Biological evaluation and mechanism of bioactivation. Eur J Med Chem 2021;:114003. [PMID: 34839998 DOI: 10.1016/j.ejmech.2021.114003] [Reference Citation Analysis]
37 Rampini D, de Araújo RV, Foitinho RE, Lourenço FR, Giarolla J. Analytical Quality by Design as an Important Tool to Determine the Best Analytical Conditions for Isoniazid and Its Respective Succinylated Prodrug. J AOAC Int 2021;104:239-47. [PMID: 33351933 DOI: 10.1093/jaoacint/qsaa087] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Huang L, Yang J, Wang T, Gao J, Xu D. Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01257-4] [Reference Citation Analysis]
39 Lu F, Zhang H, Pan W, Li N, Tang B. Delivery nanoplatforms based on dynamic covalent chemistry. Chem Commun (Camb) 2021;57:7067-82. [PMID: 34195709 DOI: 10.1039/d1cc02246f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zuwala K, Riber CF, Løvschall KB, Andersen AHF, Sørensen L, Gajda P, Tolstrup M, Zelikin AN. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. J Control Release 2018;275:53-66. [PMID: 29432822 DOI: 10.1016/j.jconrel.2018.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
41 Liang Q, Xi J, Gao XJ, Zhang R, Yang Y, Gao X, Yan X, Gao L, Fan K. A metal-free nanozyme-activated prodrug strategy for targeted tumor catalytic therapy. Nano Today 2020;35:100935. [DOI: 10.1016/j.nantod.2020.100935] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
42 Su M, Qiu L, Deng Y, Ruiz CH, Rudolf JD, Dong LB, Feng X, Cameron MD, Shen B, Duan Y, Huang Y. Evaluation of Platensimycin and Platensimycin-Inspired Thioether Analogues against Methicillin-Resistant Staphylococcus aureus in Topical and Systemic Infection Mouse Models. Mol Pharm 2019;16:3065-71. [PMID: 31244223 DOI: 10.1021/acs.molpharmaceut.9b00293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Li L, Zuo S, Dong F, Liu T, Gao Y, Yang Y, Wang X, Sun J, Sun B, He Z. Small changes in the length of diselenide bond-containing linkages exert great influences on the antitumor activity of docetaxel homodimeric prodrug nanoassemblies. Asian J Pharm Sci 2021;16:337-49. [PMID: 34276822 DOI: 10.1016/j.ajps.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Oliveri V. Selective Targeting of Cancer Cells by Copper Ionophores: An Overview. Front Mol Biosci 2022;9:841814. [DOI: 10.3389/fmolb.2022.841814] [Reference Citation Analysis]
45 Srinivasan S, Roy D, Chavas TEJ, Vlaskin V, Ho DK, Pottenger A, LeGuyader CLM, Maktabi M, Strauch P, Jackson C, Flaherty SM, Lin H, Zhang J, Pybus B, Li Q, Huber HE, Burke PA, Wesche D, Rochford R, Stayton PS. Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure. J Control Release 2021;331:213-27. [PMID: 33378692 DOI: 10.1016/j.jconrel.2020.12.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Dal Corso A, Borlandelli V, Corno C, Perego P, Belvisi L, Pignataro L, Gennari C. Fast Cyclization of a Proline-Derived Self-Immolative Spacer Improves the Efficacy of Carbamate Prodrugs. Angew Chem Int Ed Engl 2020;59:4176-81. [PMID: 31881115 DOI: 10.1002/anie.201916394] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
47 Dal Corso A, Borlandelli V, Corno C, Perego P, Belvisi L, Pignataro L, Gennari C. Fast Cyclization of a Proline‐Derived Self‐Immolative Spacer Improves the Efficacy of Carbamate Prodrugs. Angew Chem 2020;132:4205-10. [DOI: 10.1002/ange.201916394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Wang Z, Cherukupalli S, Xie M, Wang W, Jiang X, Jia R, Pannecouque C, De Clercq E, Kang D, Zhan P, Liu X. Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. J Med Chem 2022. [PMID: 35175760 DOI: 10.1021/acs.jmedchem.1c01758] [Reference Citation Analysis]
49 Zhou Y, Yang T, Liang K, Chandrawati R. Metal-organic frameworks for therapeutic gas delivery. Adv Drug Deliv Rev 2021;171:199-214. [PMID: 33561450 DOI: 10.1016/j.addr.2021.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
50 Lu S, Xia R, Wang J, Pei Q, Xie Z, Jing X. Engineering Paclitaxel Prodrug Nanoparticles via Redox-Activatable Linkage and Effective Carriers for Enhanced Chemotherapy. ACS Appl Mater Interfaces 2021;13:46291-302. [PMID: 34558902 DOI: 10.1021/acsami.1c12353] [Reference Citation Analysis]
51 Yu J, Liu Y, Zhou S, Wang Y, Wang Y. Stimuli-responsive phospholipid-drug conjugates (PDCs)-based nanovesicles for drug delivery and theranostics. Int J Pharm 2020;590:119920. [PMID: 33002539 DOI: 10.1016/j.ijpharm.2020.119920] [Reference Citation Analysis]
52 Chu B, Qu Y, He X, Hao Y, Yang C, Yang Y, Hu D, Wang F, Qian Z. ROS‐Responsive Camptothecin Prodrug Nanoparticles for On‐Demand Drug Release and Combination of Chemotherapy and Photodynamic Therapy. Adv Funct Mater 2020;30:2005918. [DOI: 10.1002/adfm.202005918] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
53 Nishimura T, Akiyoshi K. Biotransporting Biocatalytic Reactors toward Therapeutic Nanofactories. Adv Sci (Weinh) 2018;5:1800801. [PMID: 30479925 DOI: 10.1002/advs.201800801] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
54 Wang Y, Zhang C, Wu H, Feng P. Activation and Delivery of Tetrazine-Responsive Bioorthogonal Prodrugs. Molecules 2020;25:E5640. [PMID: 33266075 DOI: 10.3390/molecules25235640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Pei Q, Lu S, Zhou J, Jiang B, Li C, Xie Z, Jing X. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy. ACS Appl Mater Interfaces 2021;13:59708-19. [PMID: 34879654 DOI: 10.1021/acsami.1c19058] [Reference Citation Analysis]
56 Ianevski A, Yao R, Simonsen RM, Myhre V, Ravlo E, Kaynova GD, Zusinaite E, White JM, Polyak SJ, Oksenych V, Windisch MP, Pan Q, Lastauskienė E, Vitkauskienė A, Matukevičius A, Tenson T, Bjørås M, Kainov DE. Mono- and combinational drug therapies for global viral pandemic preparedness. iScience 2022;25:104112. [DOI: 10.1016/j.isci.2022.104112] [Reference Citation Analysis]
57 Walther R, Huynh TH, Monge P, Fruergaard AS, Mamakhel A, Zelikin AN. Ceria Nanozyme and Phosphate Prodrugs: Drug Synthesis through Enzyme Mimicry. ACS Appl Mater Interfaces 2021;13:25685-93. [PMID: 34033459 DOI: 10.1021/acsami.1c03890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wohlgemuth R. Biocatalysis - Key enabling tools from biocatalytic one-step and multi-step reactions to biocatalytic total synthesis. N Biotechnol 2021;60:113-23. [PMID: 33045418 DOI: 10.1016/j.nbt.2020.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
59 Zelikin AN. Unique enzymatic repertoire reveals the tumour. Nat Chem 2020;12:11-2. [DOI: 10.1038/s41557-019-0400-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
60 Sun G, Zhao L, Zhong R, Peng Y. The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy. Future Med Chem 2018;10:1971-96. [PMID: 30001630 DOI: 10.4155/fmc-2018-0069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
61 Lu N, Xi L, Zha Z, Wang Y, Han X, Ge Z. Acid-responsive endosomolytic polymeric nanoparticles with amplification of intracellular oxidative stress for prodrug delivery and activation. Biomater Sci 2021;9:4613-29. [PMID: 34190224 DOI: 10.1039/d1bm00159k] [Reference Citation Analysis]
62 Xu C, Yang H, Xiao Z, Zhang T, Guan Z, Chen J, Lai H, Xu X, Huang Y, Huang Z, Zhao C. Reduction-responsive dehydroepiandrosterone prodrug nanoparticles loaded with camptothecin for cancer therapy by enhancing oxidation therapy and cell replication inhibition. Int J Pharm 2021;603:120671. [PMID: 33961957 DOI: 10.1016/j.ijpharm.2021.120671] [Reference Citation Analysis]
63 Ke W, Li J, Mohammed F, Wang Y, Tou K, Liu X, Wen P, Kinoh H, Anraku Y, Chen H, Kataoka K, Ge Z. Therapeutic Polymersome Nanoreactors with Tumor-Specific Activable Cascade Reactions for Cooperative Cancer Therapy. ACS Nano 2019. [DOI: 10.1021/acsnano.8b09082] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
64 Lelieveldt LPWM, Kristyanto H, Pruijn GJM, Scherer HU, Toes REM, Bonger KM. Sequential Prodrug Strategy To Target and Eliminate ACPA-Selective Autoreactive B Cells. Mol Pharm 2018;15:5565-73. [PMID: 30289723 DOI: 10.1021/acs.molpharmaceut.8b00741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Elz AS, Trevaskis NL, Porter CJH, Bowen JM, Prestidge CA. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. J Control Release 2021;341:676-701. [PMID: 34896450 DOI: 10.1016/j.jconrel.2021.12.003] [Reference Citation Analysis]
66 Sui B, Cheng C, Shi S, Wang M, Xu P. Esterase-activatable and GSH-responsive Triptolide Nano-prodrug for the Eradication of Pancreatic Cancer. Adv Nanobiomed Res 2021;1:2100040. [PMID: 34870282 DOI: 10.1002/anbr.202100040] [Reference Citation Analysis]
67 Jarlstad Olesen MT, Walther R, Poier PP, Dagnæs‐hansen F, Zelikin AN. Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angew Chem Int Ed 2020;59:7390-6. [DOI: 10.1002/anie.201916124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
68 Wang W, Fan J, Zhu G, Wang J, Qian Y, Li H, Ju J, Shan L. Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy. Int J Nanomedicine 2020;15:2921-33. [PMID: 32425524 DOI: 10.2147/IJN.S247443] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Zhang XY, Elfarra AA. Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design. Expert Opin Drug Discov 2018;13:815-24. [PMID: 30101640 DOI: 10.1080/17460441.2018.1508207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Olesen MTJ, Winther AK, Fejerskov B, Dagnaes-hansen F, Simonsen U, Zelikin AN. Bi-Enzymatic Embolization Beads for Two-Armed Enzyme-Prodrug Therapy. Adv Therap 2018;1:1800023. [DOI: 10.1002/adtp.201800023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
71 ter Meer M, Dillion R, Nielsen SM, Walther R, Meyer RL, Daamen WF, van den Heuvel LP, van der Vliet JA, Lomme RMLM, Hoogeveen YL, Schultze Kool LJ, Schaffer JE, Zelikin AN. Innate glycosidic activity in metallic implants for localized synthesis of antibacterial drugs. Chem Commun 2019;55:443-6. [DOI: 10.1039/c8cc08737g] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Peng Y, Shi Z, Liang Y, Ding K, Wang Y. Targeting the tumor microenvironment by an enzyme-responsive prodrug of tubulin destabilizer for triple-negative breast cancer therapy with high safety. Eur J Med Chem 2022;236:114344. [PMID: 35405397 DOI: 10.1016/j.ejmech.2022.114344] [Reference Citation Analysis]
73 Ferhati X, Salas-Cubero M, Garrido P, García-Sanmartín J, Guerreiro A, Avenoza A, Busto JH, Peregrina JM, Martínez A, Jiménez-Moreno E, Bernardes GJL, Corzana F. Bioorthogonal Self-Immolative Linker Based on Grob Fragmentation. Org Lett 2021;23:8580-4. [PMID: 34694118 DOI: 10.1021/acs.orglett.1c03299] [Reference Citation Analysis]
74 Love AC, Tran SH, Prescher JA. Caged Cumate Enables Proximity-Dependent Control Over Gene Expression. Chembiochem 2021;22:2440-8. [PMID: 34031982 DOI: 10.1002/cbic.202100158] [Reference Citation Analysis]
75 Piao X, Yin H, Guo S, Wang H, Guo P. RNA Nanotechnology to Solubilize Hydrophobic Antitumor Drug for Targeted Delivery. Adv Sci (Weinh) 2019;6:1900951. [PMID: 31763137 DOI: 10.1002/advs.201900951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
76 Plunk MA, Alaniz A, Olademehin OP, Ellington TL, Shuford KL, Kane RR. Design and Catalyzed Activation of Tak-242 Prodrugs for Localized Inhibition of TLR4-Induced Inflammation. ACS Med Chem Lett 2020;11:141-6. [PMID: 32071680 DOI: 10.1021/acsmedchemlett.9b00518] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
77 Walther R, Nielsen SM, Christiansen R, Meyer RL, Zelikin AN. Combatting implant-associated biofilms through localized drug synthesis. J Control Release 2018;287:94-102. [PMID: 30138714 DOI: 10.1016/j.jconrel.2018.08.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
78 Li S, Shan X, Wang Y, Chen Q, Sun J, He Z, Sun B, Luo C. Dimeric prodrug-based nanomedicines for cancer therapy. J Control Release 2020;326:510-22. [PMID: 32721523 DOI: 10.1016/j.jconrel.2020.07.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
79 Walther R, Monge P, Pedersen AB, Benderoth A, Pedersen JN, Farzadfard A, Mandrup OA, Howard KA, Otzen DE, Zelikin AN. Per-glycosylation of the Surface-Accessible Lysines: One-Pot Aqueous Route to Stabilized Proteins with Native Activity. Chembiochem 2021;22:2478-85. [PMID: 33998129 DOI: 10.1002/cbic.202100228] [Reference Citation Analysis]
80 Yang T, Fruergaard AS, Winther AK, Zelikin AN, Chandrawati R. Zinc Oxide Particles Catalytically Generate Nitric Oxide from Endogenous and Exogenous Prodrugs. Small 2020;16:1906744. [DOI: 10.1002/smll.201906744] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
81 Cheng L, Zhang F, Wang S, Pan X, Han S, Liu S, Ma J, Wang H, Shen H, Liu H, Yuan Q. Activation of Prodrugs by NIR‐Triggered Release of Exogenous Enzymes for Locoregional Chemo‐photothermal Therapy. Angew Chem 2019;131:7810-4. [DOI: 10.1002/ange.201902476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Wang C, Shao C, Fang Y, Wang J, Dong N, Shan A. Binding loop of sunflower trypsin inhibitor 1 serves as a design motif for proteolysis-resistant antimicrobial peptides. Acta Biomater 2021;124:254-69. [PMID: 33508505 DOI: 10.1016/j.actbio.2021.01.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
83 Delahousse J, Skarbek C, Paci A. Prodrugs as drug delivery system in oncology. Cancer Chemother Pharmacol 2019;84:937-58. [DOI: 10.1007/s00280-019-03906-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
84 Li Y, Zhu J, Kang T, Chen Y, Liu Y, Huang Y, Luo Y, Huang M, Gou M. Co-assembling FRET nanomedicine with self-indicating drug release. Chem Commun 2018;54:11618-21. [DOI: 10.1039/c8cc06792a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
85 Calatrava-Pérez E, Marchetti LA, McManus GJ, Lynch DM, Elmes RBP, Williams DC, Gunnlaugsson T, Scanlan EM. Real-Time Multi-Photon Tracking and Bioimaging of Glycosylated Theranostic Prodrugs upon Specific Enzyme Triggered Release. Chemistry 2021. [PMID: 34820925 DOI: 10.1002/chem.202103858] [Reference Citation Analysis]
86 Maslah H, Skarbek C, Pethe S, Labruère R. Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. European Journal of Medicinal Chemistry 2020;207:112670. [DOI: 10.1016/j.ejmech.2020.112670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
87 Jarlstad Olesen MT, Walther R, Poier PP, Dagnæs‐hansen F, Zelikin AN. Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angew Chem 2020;132:7460-6. [DOI: 10.1002/ange.201916124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 van der Meel R, Chen S, Zaifman J, Kulkarni JA, Zhang XRS, Tam YK, Bally MB, Schiffelers RM, Ciufolini MA, Cullis PR, Tam YYC. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small 2021;:e2103025. [PMID: 34337865 DOI: 10.1002/smll.202103025] [Reference Citation Analysis]
89 Jimidar CC, Grunenberg J, Karge B, Fuchs HLS, Brönstrup M, Klahn P. Masked Amino Trimethyl Lock (H2 N-TML) Systems: New Molecular Entities for the Development of Turn-On Fluorophores and Their Application in Hydrogen Sulfide (H2 S) Imaging in Human Cells. Chemistry 2021. [PMID: 34713944 DOI: 10.1002/chem.202103525] [Reference Citation Analysis]
90 Ono K, Hashimoto H, Katayama T, Ueda N, Nagahama K. Injectable Biocatalytic Nanocomposite Hydrogel Factories for Focal Enzyme-Prodrug Cancer Therapy. Biomacromolecules 2021;22:4217-27. [PMID: 34546743 DOI: 10.1021/acs.biomac.1c00778] [Reference Citation Analysis]
91 Winther AK, Fejerskov B, Ter Meer M, Jensen NBS, Dillion R, Schaffer JE, Chandrawati R, Stevens MM, Schultze Kool LJ, Simonsen U, Zelikin AN. Enzyme Prodrug Therapy Achieves Site-Specific, Personalized Physiological Responses to the Locally Produced Nitric Oxide. ACS Appl Mater Interfaces 2018;10:10741-51. [PMID: 29570264 DOI: 10.1021/acsami.8b01658] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
92 Procházková E, Filo J, Cigáň M, Baszczyňski O. Sterically-Controlled Self-Immolation in Phosphoramidate Linkers Triggered by Light: Sterically-Controlled Self-Immolation in Phosphoramidate Linkers Triggered by Light. Eur J Org Chem 2020;2020:897-906. [DOI: 10.1002/ejoc.201901882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
93 Bhagat SD, Singh U, Mishra RK, Srivastava A. An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy. ChemMedChem 2018;13:2073-9. [DOI: 10.1002/cmdc.201800367] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
94 Muthiah G, Jaiswal A. Can the Union of Prodrug Therapy and Nanomedicine Lead to Better Cancer Management? Advanced NanoBiomed Research 2022;2:2100074. [DOI: 10.1002/anbr.202100074] [Reference Citation Analysis]
95 Ren C, Liu H, Lv F, Zhao W, Gao S, Yang X, Jin Y, Tan Y, Zhang J, Liang X, Li Z. Prodrug-Based Nanoreactors with Tumor-Specific In Situ Activation for Multisynergistic Cancer Therapy. ACS Appl Mater Interfaces 2020;12:34667-77. [DOI: 10.1021/acsami.0c09489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Grosu E, Froidevaux R, Carja G. Horseradish peroxidase-AuNP/LDH heterostructures: influence on nanogold release and enzyme activity. Gold Bull 2019;52:87-97. [DOI: 10.1007/s13404-019-00256-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
97 Wang H, Monroe M, Leslie F, Flexner C, Cui H. Supramolecular nanomedicines through rational design of self-assembling prodrugs. Trends Pharmacol Sci 2022:S0165-6147(22)00053-0. [PMID: 35459589 DOI: 10.1016/j.tips.2022.03.003] [Reference Citation Analysis]
98 Huang R, Li CH, Cao-Milán R, He LD, Makabenta JM, Zhang X, Yu E, Rotello VM. Polymer-Based Bioorthogonal Nanocatalysts for the Treatment of Bacterial Biofilms. J Am Chem Soc 2020;142:10723-9. [PMID: 32464057 DOI: 10.1021/jacs.0c01758] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
99 Intagliata S, Modica MN, Santagati LM, Montenegro L. Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update. Antioxidants (Basel) 2019;8:E244. [PMID: 31349656 DOI: 10.3390/antiox8080244] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
100 A. M. Subbaiah M, Mandlekar S, Desikan S, Ramar T, Subramani L, Annadurai M, Desai SD, Sinha S, Jenkins SM, Krystal MR, Subramanian M, Sridhar S, Padmanabhan S, Bhutani P, Arla R, Singh S, Sinha J, Thakur M, Kadow JF, Meanwell NA. Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir. J Med Chem 2019;62:3553-74. [DOI: 10.1021/acs.jmedchem.9b00002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
101 Walsh DJ, Livinghouse T, Durling GM, Arnold AD, Brasier W, Berry L, Goeres DM, Stewart PS. Novel phenolic antimicrobials enhanced activity of iminodiacetate prodrugs against biofilm and planktonic bacteria. Chem Biol Drug Des 2021;97:134-47. [PMID: 32844569 DOI: 10.1111/cbdd.13768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Caban M, Stepnowski P. How to decrease pharmaceuticals in the environment? A review. Environ Chem Lett 2021;19:3115-38. [DOI: 10.1007/s10311-021-01194-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
103 Chojnacki K, Wińska P, Karatsai O, Koronkiewicz M, Milner-Krawczyk M, Wielechowska M, Rędowicz MJ, Bretner M, Borowiecki P. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols-Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties. Int J Mol Sci 2021;22:6261. [PMID: 34200807 DOI: 10.3390/ijms22126261] [Reference Citation Analysis]
104 Nguyen A, Böttger R, Li SD. Recent trends in bioresponsive linker technologies of Prodrug-Based Self-Assembling nanomaterials. Biomaterials 2021;275:120955. [PMID: 34130143 DOI: 10.1016/j.biomaterials.2021.120955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Li X, Hou Y, Meng X, Ge C, Ma H, Li J, Fang J. Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells. Angew Chem Int Ed Engl 2018;57:6141-5. [PMID: 29582524 DOI: 10.1002/anie.201801058] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
106 Li J, Kataoka K. Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation. J Am Chem Soc 2021;143:538-59. [PMID: 33370092 DOI: 10.1021/jacs.0c09029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
107 Tian C, Guo J, Miao Y, Zheng S, Sun B, Sun M, Ye Q, Liu W, Zhou S, Kamei KI, He Z, Sun J. Triglyceride-Mimetic Structure-Gated Prodrug Nanoparticles for Smart Cancer Therapy. J Med Chem 2021;64:15936-48. [PMID: 34723524 DOI: 10.1021/acs.jmedchem.1c01328] [Reference Citation Analysis]
108 Miao YB, Lin YJ, Chen KH, Luo PK, Chuang SH, Yu YT, Tai HM, Chen CT, Lin KJ, Sung HW. Engineering Nano- and Microparticles as Oral Delivery Vehicles to Promote Intestinal Lymphatic Drug Transport. Adv Mater 2021;:e2104139. [PMID: 34596293 DOI: 10.1002/adma.202104139] [Reference Citation Analysis]
109 Walther R, Winther AK, Fruergaard AS, van den Akker W, Sørensen L, Nielsen SM, Jarlstad olesen MT, Dai Y, Jeppesen HS, Lamagni P, Savateev A, Pedersen SL, Frich CK, Vigier‐carrière C, Lock N, Singh M, Bansal V, Meyer RL, Zelikin AN. Identification and Directed Development of Non‐Organic Catalysts with Apparent Pan‐Enzymatic Mimicry into Nanozymes for Efficient Prodrug Conversion. Angew Chem Int Ed 2019;58:278-82. [DOI: 10.1002/anie.201812668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
110 Meghwanshi GK, Kaur N, Verma S, Dabi NK, Vashishtha A, Charan PD, Purohit P, Bhandari HS, Bhojak N, Kumar R. Enzymes for pharmaceutical and therapeutic applications. Biotechnol Appl Biochem 2020;67:586-601. [PMID: 32248597 DOI: 10.1002/bab.1919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
111 Gisbert-garzarán M, Manzano M, Vallet-regí M. Self-immolative chemistry in nanomedicine. Chemical Engineering Journal 2018;340:24-31. [DOI: 10.1016/j.cej.2017.12.098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
112 Li X, Hou Y, Meng X, Ge C, Ma H, Li J, Fang J. Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells. Angew Chem 2018;130:6249-53. [DOI: 10.1002/ange.201801058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]